Giant Cell Arteritis Pipeline 2025: Groundbreaking Clinical Advancements by 80+ Global Leaders - DelveInsight | Featuring Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, Dr Reddys Laboratories

With Giant Cell Arteritis reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Giant Cell Arteritis pipeline comprises 6+ pharmaceutical and biotech companies actively developing 6+ therapeutic candidates targeting Giant Cell Arteritis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Giant Cell Arteritis Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders, including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Giant Cell Arteritis Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Giant Cell Arteritis Drug Development @ https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Giant Cell Arteritis Pipeline Report

DelveInsight's Giant Cell Arteritis pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Giant Cell Arteritis treatment.
In July, 2025, Novartis' Cosentyx (secukinumab) failed to meet its primary endpoint in the Phase III GCAptAIN trial, failing to significantly improve the rate of sustained remission at 52 weeks compared to placebo. There were numerical reductions in steroid use, but results were not statistically significant .
In April, 2025, Abbie's Rinvoq (upadacitinib) received FDA approval as the first oral JAK inhibitor for adult GCA patients. The approval is based on Phase III SELECT‐GCA trial results, in which 46.4% of patients taking 15 mg daily alongside a steroid taper achieved sustained remission (weeks 12-52), compared to 29% in the placebo group (p = 0.002)
Key Giant Cell Arteritis companies such as Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, Dr Reddys Laboratories, and others are evaluating new drugs for Giant Cell Arteritis to improve the treatment landscape.
Promising Giant Cell Arteritis pipeline therapies in various stages of development include Secukinumab, Upadacitinib, and others.

Giant Cell Arteritis Overview:

Giant cell arteritis (GCA) is the most prevalent form of vasculitis affecting individuals over the age of 50, involving inflammation of medium to large-sized arteries. This inflammation alters the vessel walls, impairing blood flow. The temporal and other cranial arteries are commonly involved-a condition referred to as cranial GCA-but inflammation can also affect the aorta and other large vessels, known as large-vessel GCA, which may present with different symptoms. If not diagnosed and treated early, GCA can lead to serious complications such as sudden, irreversible blindness.

When cranial arteries are affected, symptoms may include one-sided or occipital headaches, jaw claudication, scalp tenderness, arm pain, visual disturbances like double vision, and visible, tender swelling of the temporal artery. Systemic symptoms-more typical in large-vessel GCA-can include fever, weight loss, anorexia, and polymyalgia. The underlying cause of GCA remains unclear, but it is believed to be driven by the immune system attacking the body's own blood vessels.

GCA is closely linked to polymyalgia rheumatica (PMR), an inflammatory condition that co-occurs in about 40-60% of GCA cases, while 15-20% of people with PMR may develop GCA. Treatment primarily involves corticosteroids to manage symptoms and reduce recurrence, along with immunosuppressive medications to control the immune response.

Download the Giant Cell Arteritis sample report to know in detail about the Giant Cell Arteritis treatment market @ https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Giant Cell Arteritis Pipeline Analysis
The Giant Cell Arteritis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Giant Cell Arteritis Market.

Categorizes Giant Cell Arteritis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Giant Cell Arteritis drugs under development based on:

Stage of development

Giant Cell Arteritis Route of administration

Target receptor

Monotherapy vs. combination therapy

Giant Cell Arteritis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Giant Cell Arteritis Licensing agreements

Funding and investment activities supporting future Giant Cell Arteritis market advancement.

Unlock key insights into emerging Giant Cell Arteritis therapies and market strategies here: https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Giant Cell Arteritis Emerging Drugs

Secukinumab: Novartis

Secukinumab is a fully human monoclonal antibody (IgG1/κ) that targets interleukin-17A (IL-17A), a key proinflammatory cytokine involved in chronic immune-mediated inflammatory diseases like plaque psoriasis. By blocking IL-17A, secukinumab helps reduce inflammation associated with these conditions.

The drug was first approved in Japan in December 2014, followed by the European Commission on January 15, 2015, and the U.S. FDA on January 21, 2015. It is currently approved for treating plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab is now being evaluated in Phase III clinical trials for its potential use in treating Giant Cell Arteritis (GCA).

Upadacitinib: AbbVie

Upadacitinib is an oral, selective Janus kinase 1 (JAK1) inhibitor approved for the treatment of several inflammatory conditions, including moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis-particularly in patients who have had inadequate responses to previous therapies. It was approved by the FDA in August 2019 for multiple indications such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. The European Commission granted approval in December 2019. Marketed under the brand name RINVOQ, it is currently undergoing Phase III clinical trials for potential use in treating Giant Cell Arteritis.

Giant Cell Arteritis Pipeline Therapeutic Assessment

Giant Cell Arteritis Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Giant Cell Arteritis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Giant Cell Arteritis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Giant Cell Arteritis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Giant Cell Arteritis therapies and key Giant Cell Arteritis companies: https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Giant Cell Arteritis Current Treatment Patterns
4. Giant Cell Arteritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Giant Cell Arteritis Late-Stage Products (Phase-III)
7. Giant Cell Arteritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Giant Cell Arteritis Discontinued Products
13. Giant Cell Arteritis Product Profiles
14. Giant Cell Arteritis Key Companies
15. Giant Cell Arteritis Key Products
16. Dormant and Discontinued Products
17. Giant Cell Arteritis Unmet Needs
18. Giant Cell Arteritis Future Perspectives
19. Giant Cell Arteritis Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Giant Cell Arteritis pipeline reports offerings: https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.